Aspergillus oryzae as a host for SARS-CoV-2 RBD and NTD expression-Reference-Cited by-同舟云学术

Aspergillus oryzae as a host for SARS-CoV-2 RBD and NTD expression

Published:2024-06-07 Issue:2 Volume:33 Page:9-20
ISSN:2687-3761
Container-title:Biotech Studies
language:en
Short-container-title:Biotech Studies

Author:

Karaman Elif¹^ORCID,Uysal Serdar¹^ORCID

Affiliation:

1. BEZMI ALEM FOUNDATION UNIVERSITY, INSTITUTE OF LIFE SCIENCES AND BIOTECHNOLOGY, DEPARTMENT OF BIOTECHNOLOGY

Abstract

The COVID-19 pandemic has increased demand for effective diagnostics, and extensive research has been conducted on the N-terminal domain (NTD) and the receptor-binding domain (RBD) of the SARS-CoV-2 spike glycoprotein, which are critical for viral binding. This study focuses on the expression of NTD and RBD in pyrG auxotrophic Aspergillus oryzae for the first time. Recombinant NTD and RBD were expressed as glucoamylase-fusion proteins and purified using metal affinity chromatography. Size-exclusion chromatography was used to confirm the correct folding and purity of the recombinant proteins. Employing an enzyme-linked immunosorbent assay, the binding ability of the fusion proteins to human anti-IgG antibodies in serum samples was evaluated. The results indicated a significant and concentration-dependent interaction, affirming the functionality of the NTD and RBD fusion proteins and establishing their efficacy in antigen-antibody interactions. This study not only elucidates the usage potential of the fusion proteins in immunoassays but also addresses the suitability of the A. oryzae expression system as a biotechnological platform to produce SARS-CoV-2 proteins. Furthermore, this study lays the foundation for scalable and cost-effective mass production of effective NTD and RBD proteins in A. oryzae, opening up a new era of COVID-19 research, vaccine development, and immunoassay design.

Publisher

Field Crops Central Research Institute

Reference45 articles.

1. Argentinian AntiCovid Consortium. (2020). Structural and functional comparison of SARS-CoV-2-spike receptor binding domain produced in Pichia pastoris and mammalian cells. Nature Scientific Reports, 10(1), 21779. https://doi.org/10.1038/s41598-020-78711-6

2. Azar, L. M., Öncel, M. M., Karaman, E., Soysal, L. F., Fatima, A., Choi, S. B., Eyupoglu, A. E., Erman, B., Khan, A. M., & Uysal, S. (2023). Human ACE2 orthologous peptide sequences show better binding affinity to SARS-CoV-2 RBD domain: Implications for drug design. Computational and Structural Biotechnology Journal, 21, 4096-4109. https://doi.org/10.1016/j.csbj.2023.07.022

3. Balasubramaniyam, A., Ryan, E., Brown, D., Hamza, T., Harrison, W., Gan, M., Sankhala, R. S., Chen, W., Martinez, E. J., Jensen, J. L., Dussupt, V., Mendez-Rivera, L., Mayer, S., King, J., Michael, N. L., Regules, J., Krebs, S., Rao, M., Matyas, G. R., Joyce, M. G., Batchelor, A. H., Gromowski, G. D., & Dutta, S. (2022). Unglycosylated soluble SARS-CoV-2 receptor binding domain (RBD) produced in E.coli combined with the army liposomal formulation containing QS21 (ALFQ) elicits neutralizing antibodies against mismatched variants. Vaccines, 11(1), 42. https://doi.org/10.3390/vaccines11010042

4. Bastos, M. L., Tavaziva, G., Abidi, S. K., Campbell, J. R., Haraoui, L. P., Johnston, J. C., Lan, Z., Law, S., MacLean, E., Trajman, A., Menzies, D., Benedetti, A., & Khan, F. A. (2020). Diagnostic accuracy of serological tests for COVID-19: Systematic review and meta-analysis. BMJ, 370, 2516. https://doi.org/10.1136/bmj.m2516

5. Brindha, S., & Kuroda, Y. (2022). A multi-disulfide receptor-binding domain (RBD) of the SARS-CoV-2 spike protein expressed in E. coli using a SEP-tag produces antisera interacting with the mammalian cell expressed spike